Fertility Regulation in Male Rats by Implemented Tetraazamacrocyclic Compounds of Iron(II): Synthetic, Spectroscopic, and Applied Aspects With Toxicological Screening

Ashu Chaudhary and Ran Vir Singh

Department of Chemistry, University of Rajasthan, Jaipur 302 004, Rajasthan, India

Received 12 August 2004; Revised 18 October 2004; Accepted 25 November 2004

Antifertility and histopathological investigations were carried out on reproductive organs of male albino rats induced by tetraaza-macroyclic complexes of iron(II). The complexes were synthesized by the template condensation of 1,2-diaminoethane, 1,3-diaminopropane with succinic acid and phthalic acid in 2 : 2 molar ratios which are abbreviated as \([\text{Fe(TAML}^n\text{OAc}])\) \((n = 1 \text{ or } 2)\) and TAML\(^n\) represents tetraazamacrocyclic ligand). The complexes have been characterized by elemental analysis, conductivity measurements, IR, and electronic spectra.

Copyright © 2006 A. Chaudhary and R. V. Singh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Today, rapidly expanding population and limited sources are thought to be the most pressing global problems. This rapid increase in the world population has multiplied the benefits of economical and technological advancements. Fertility control is very essential for maintaining satisfactory standards in the developing countries. There is an increasing international recognition for the need to control human fertility. Needless to say there is an immediate need for an inexpensive, safe, and effective as well as universally acceptable contraceptive. For evolution of such an ideal method for control of human fertility, it is necessary that the reproductive process both of male and female need to be more intensively investigated.

The population of India is multiplying at an alarming rate and has almost crossed one billion by this time. Fertility regulation has therefore become the major concern for the people of all the walks of life. The dramatic success of oral contraceptives in women and the lack of pill for man have stimulated research in male fertility control. The development of new and improved contraception agent for men has lagged behind the development of female contraceptives.

The male, an integral part of the family unit, has largely been sidelined by family planners. Currently, efforts are being made to develop a male contraceptive agent, which would inhibit fertility without affecting sex accessory function and libido. In this endeavor, a variety of synthetic compounds have been evaluated in males of laboratory species of mammals [1–5]. The results obtained are also encouraging. Therefore, this approach may form the basis for clinical regulation of male fertility in future. Inorganic compounds have also been investigated and applied for antifertility activity only and have not been screened for toxicological effect [6–9]. In this context, the present communication deals with the synthesis, characterization, and contraceptive efficacy of iron(II) tetraazamacrocyclic complexes. The complexes screened were investigated for their antifertility efficacy at biochemical and histopathological levels.

The tetraazamacrocyclic complexes of iron(II) reported in this paper have been synthesized for the first time. The complexes have been isolated in pure form through crystallization. These show good antifertility activity and may be useful for medicinal purpose. Further, it has been reported that manganese salts (chloride, nitrate, and acetate) cause loss of testicular germ cells in rats and rabbits, and decreased libido and impotency were noted in men occupationally exposed to manganese [10]. Similarly, macrocyclic complexes of manganese(II) and iron(II) exhibit a broad spectrum of antimicrobial, antiinflammatory, analgesic, and antifertility
activity [11]. The above discussion has inspired us to synthesize tetraazamacrocyclic complexes of iron(II) and then screen them for their antifertility activity.

EXPERIMENTS

Synthesis

Materials and methods

The chemicals including succinic acid, phthalic acid (Fluka chemie AG, Industriestrasse, CH 9471, Buchs, Switzerland), 1,2-diaminoethane, 1,3-diaminopropane (Merck Limited India, Shiv Sagar Estate A, Dr. Annie Besant Road, Worli, Mumbai 400018), and Fe(CH$_3$COO)$_2$ (BDH) were used.

Synthesis of 2,5,10,13-tetraoxo-1,6,9,14-tetraazacyclohexadecane iron(II): [Fe(TAML1)(OAc)$_2$]

The reaction was carried out in 1 : 2 : 2 molar ratios. Fe–(CH$_3$COO)$_2$ (5 mmol) was dissolved in methanol (25 mL) and cooled in an ice bath. To this solution, taken in a 100 mL round bottom flask, was added 1,2-diaminoethane [corresponding to Fe(CH$_3$COO)$_2$] in methanol (25 mL). The resulting mixture was stirred for 25–30 h. The solid product was isolated by filtration, repeatedly washed with the same solvent, and dried in vacuo. The compound was recrystallized in benzene and again dried in vacuo.

Synthesis of 3,4,12,13-dibenzo-2,5,11,14-tetraoxo-1,6,10,15-tetraazacyclododecane iron(II): [Fe(TAML2)(OAc)$_2$]

The same experimental procedure as for [Fe(TAML1)(OAc)$_2$] was used. The reagents used for this purpose are 1,3-diaminopropane and phthalic acid.

Analytical methods and physical measurements

Nitrogen was estimated by Kjeldahl’s method. Iron was estimated gravimetrically. Carbon and hydrogen analyses were performed at Regional Sophisticated Instrumentation Centre of Central Research Drugs Institute, Lucknow. Conductivity measurements were made with a Systronic (Model 305) conductivity bridge in dry dimethylformamide. Molecular weights were determined by the Rast Camphor method. The IR spectra of the solid samples were recorded as KBr discs on a Nicolet Magna FTIR-550 spectrophotometer. Electronic spectra were recorded, in the range 200–600 nm, using methanol as the solvent on a UV-160A Shimadzu spectrophotometer.

Antifertility activity

In the present investigations, healthy adult male albino rats (Rattus norvegicus) each having weight between 200–250 g of proven fertility were used. These were preferred over other laboratory mammals because of their medium size, relatively double nature, easy in handling and maintenance, size, relatively docile nature, covertly observable sex and libido, and in having a relatively short gestation period of 23–30 days. Animals were regularly checked for any disease and if found infected were isolated and treated. Animals were fed on a diet of rat feed pellets obtained from Hindustan Lever Ltd, Mumbai, India, and soaked gram. Water was provided ad libitum.

In these investigations, doses of the compounds mixed in vehicle (olive oil) were given orally with the help of hypodermic syringe having pearl point needle, for 60 days and withdrawal (recovery) for 30 days (Table 1).

The LD$_{50}$ is a statistically derived single dose of a substance that can be expected to cause death in 50% of the animals. In a prohibited analysis method of LD$_{50}$, the selected dose levels should bracket the expected LD$_{50}$ value with at least one dose level higher than the expected LD$_{50}$ but not causing 100% mortality and one dose level below the expected LD$_{50}$ but not causing 0% mortality. Toxicity of the complexes was determined by calculating the LD$_{50}$ values. Symptoms of poisoning and mortality were observed and results of toxicity were analyzed for determination of LD$_{50}$ values of the complexes. On the basis of LD$_{50}$ values the present (only single) dose of the compounds were decided for the experiment.

Fertility test

After the completion of the treatment, the fertility test was done. On day 61, the animals were autopsied and blood was extracted from heart. The serum was separated and used for serum biochemistry. Reproductive tissues (testis, epididymis, vas deferens, seminal vesicle, and ventral prostate) and vital organs (liver, kidney, heart, and adrenal) were blotted free of blood, weighed, and used for tissue biochemistry and histology.

Body and organ weights

Initial and final body weights of animals were taken before and after the treatment. The mean value of each of the tissues was calculated.

Spermatozoa motility and count

The spermatozoa motility was determined according to the method of Prasad et al [12] using WBC counting Neubauer chamber of a hemocytometer and was expressed as million spermatozoa/mL suspension.
Biochemical studies

Protein was estimated by Lowry et al.’s [13] method. Sialic acid was estimated by the procedure given by Warren [14]. Cholesterol was done as per the method of Zlatkis et al [15]. Glycogen was estimated by the method of Montgomery [16]. Fructose was done by the method of Foreman et al [17]. Ascorbic acid was estimated by the method of Roe and Kuether [18]. Acid phosphatase and alkaline phosphatase were measured by the method of Fiske and Subbarow [19].

RESULTS AND DISCUSSION

Synthetic

The complexes are colored solids and soluble in most of the organic solvents like methanol, benzene, dichloromethane, tetrahydrofuran, and dimethylformamide. Their non-electrolytic nature was confirmed by low molar conductance values 15–23 Ohm−1 cm2 mol−1. Physical properties and analytical data of the complexes are given in Table 2.

IR spectra

The IR spectra of the starting materials and their iron complexes were recorded and their comparative study confirmed the formation of macroyclic complexes with the proposed coordination pattern. The bands observed in the region 3420–3531 cm−1 attributed to –NH2 of amino and 2500–2590 cm−1 attributed to –OH of the carboxylic acid. Both of these bands (–NH2 and –OH) disappeared in the complexes, confirming the cyclization. A single sharp band is observed at 3132 cm−1 for [Fe(TAML1)(CH3COO)2] and at 3251 cm−1 for [Fe(TAML2)(CH3COO)2] due to ν(N–H) of the amide group. The appearance of four bands at 1649, 1565, 1271, and 638 cm−1 for [Fe(TAML1)(CH3COO)2] and 1687, 1561, 1249, and 670 cm−1 for [Fe(TAML2)(CH3COO)2] are due to the amide I, amide II, amide III, and amide IV vibrations, respectively.

To distinguish between these structures (enolic and amide), we have synthesized the free ligands and recorded their IR spectra. Surprisingly, there were no bands for the azomethine group (>C=N) in the IR spectra of the complexes. This clearly indicated that the amide structure is the real structure in this case and not the enolic structure. The νasym and νsym CO of the acetate group appear at 1480 and 1330 cm−1 (Δν150 cm−1) suggesting the bonding mode of acetate group [20]. A sharp band observed at 482 and 487 cm−1 ascribed to the Fe–O stretching vibrations in the complexes [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2], respectively. Similar results have also been confirmed and reported by other authors [21].

Electronic spectra

A weak intensity band exhibited at 11904 and 11278 cm−1 for [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2], respectively, is assigned to the 5T2 → 5Eg transitions consistent with an octahedral geometry for iron(II) complexes. These assignments are also in tune with the results of Lobana et al [22] and Chaudhary et al [23] for high-spin octahedral iron(II) system.

On the basis of the above spectral studies, the derivatives have been assigned the following structures with hexacoordinated iron atom (Figure 1).

Antifertility activity

Body and organ weights

The data revealed that the body weights of rats were not much altered after the treatment of [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2], however, in both the treated groups, a general decrease in the reproductive organ weights was observed in relation to the control. A significant reduction was observed in weights of testis (P < 0.01), epididymis (p < 0.001), seminal vesicle (p < 0.01) and ventral prostate (p < 0.001) in [Fe(TAML1)(CH3COO)2] treated animals. The treatment of [Fe(TAML2)(CH3COO)2] also resulted in a significant decrease in the weights of testis (p < 0.001), epididymis (P < 0.001), vas deferens (p < 0.01), seminal vesicle (p < 0.001), and ventral prostate (p < 0.01).

After the withdrawal of both of the compounds, the results favour that [Fe(TAML1)(CH3COO)2] was comparatively better in treatment. The vital organs data (Table 3) also show similar results as reported for reproductive organs in Table 4.

Spermatozoa motility and count

The spermatozoa motility of [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2] treated rats showed that the

| Compound | Color and MP (°C) | Yield (%) | Analysis % found (calcd.) | Mol. wt. found (calcd.) |
|----------|------------------|-----------|--------------------------|------------------------|
| [Fe(TAML1)(CH3COO)2] | Brown | 63 | 41.81 (41.96) | 4.62 (5.72) | 11.28 (11.23) | 11.74 (12.19) | 439 (458) |
| [Fe(TAML2)(CH3COO)2] | Brown | 67 | 53.50 (53.66) | 5.10 (5.20) | 8.78 (9.63) | 9.15 (9.60) | 559 (582) |
sperms were sluggishly motile without any forward progression. The motility percent after [Fe(TAML¹)(CH₃COO)₂] treatment declined significantly (p < 0.001). Following withdrawal of the treatment, the sperms were actively motile showing forward progression and the sperm motility percentage of the above groups recovered completely to normal level (Table 5). The sperm density of cauda epididymis and testicular sperm density diminished significantly (p < 0.001) in [Fe(TAML¹)(CH₃COO)₂] and [Fe(TAML²)(CH₃COO)₂] treated rats and restored partially following 30 days withdrawal in both the groups (Table 5).

**Fertility test**

Normal proestrous females after mating with the males of proven fertility deliver on average 8–10 pups per female. The treated animals exhibited normal libido and mating behaviour, however, in [Fe(TAML¹)(CH₃COO)₂] treated animals, the fertility test gave 90% negative fertility rate and in [Fe(TAML²)(CH₃COO)₂] treated group, the fertility test was 72% negative. Following withdrawal of the drug, 25% recovery in fertility rate was observed in [Fe(TAML¹)(CH₃COO)₂] treated group of the animals, whereas 42% recovery

---

### Table 3: Vital organ weight (mg/100 g body wt.) in [Fe(TAML¹)(CH₃COO)₂] and [Fe(TAML²)(CH₃COO)₂] treated and withdrawal group of rats. Values are mean ± SE.

| Group                          | Liver (mg)       | Vital organ (mg) | Heart (mg)     | Kidney (mg)    | Adrenal (mg)  |
|--------------------------------|------------------|------------------|----------------|----------------|---------------|
| Control                        | 3038.60 ± 180.20 | 505.00 ± 10.8    | 254.70 ± 8.39  | 288.08 ± 4.35  | 9.40 ± 0.40   |
| [Fe(TAML¹)(CH₃COO)₂]           | 3220.54 ± 110.42 | 255.00 ± 10.8    | 272.09 ± 6.54  | 330.20 ± 17.25 | 12.02 ± 0.60  |
| Withdrawal (30 days)           | 3550.29 ± 140.39 | 255.70 ± 6.54    | 335.70 ± 7.45  | 340.55 ± 7.54  | 13.95 ± 0.89  |
| [Fe(TAML²)(CH₃COO)₂]           | 2579.50 NS ± 360.50 | 255.70 ± 6.54  | 255.70 ± 9.09  | 255.60 ± 4.47  | 11.78 ± 0.52  |
| Withdrawal (30 days)           | 4452.86 ± 130.23 | 255.70 ± 9.09    | 346.60 ± 18.95 | 348.10 ± 20.02 | 7.99 ± 0.73   |

NS = not significant

---

### Table 4: Body (g) and reproductive organ weights (mg/100 g body wt.) in [Fe(TAML¹)(CH₃COO)₂] and [Fe(TAML²)(CH₃COO)₂] treated and withdrawal group of rats. Values are mean ± SE.

| Group                          | Body Wt. (g)       | Reproductive organ (mg) | Testis | Epididymis | Vas deferens | Seminal vesicle | Ventral prostate |
|--------------------------------|--------------------|-------------------------|--------|------------|--------------|-----------------|-----------------|
|                                | Initial            | Final                   |        |            |              |                 |                 |
| Control                        | 202.50 ± 5.45      | 212.50 ± 4.51           | 641.09 ± 12.50 | 243.13 ± 4.86 | 42.05 ± 1.50 | 207.21 ± 8.33 | 123.92 ± 3.82   |
| [Fe(TAML¹)(CH₃COO)₂]           | 163.60 ± 18.00     | 194.00 ± 16.05          | 541.16 ± 25.80 | 201.37 ± 5.70 | 40.90 ± 0.82 | 147.67 ± 13.67 | 95.40 ± 1.32    |
| Withdrawal (30 days)           | 210.72 ± 18.62     | 240.27 ± 18.62          | 505.16 ± 20.02 | 184.83 ± 7.12 | 50.40 ± 2.76 | 138.60 ± 5.48 | 180.79 ± 6.96   |
| [Fe(TAML²)(CH₃COO)₂]           | 285.20 ± 3.30      | 255.20 ± 1.87           | 540.35 ± 16.10 | 160.84 ± 9.19 | 35.25 ± 0.345 | 128.07 ± 7.89 | 96.39 ± 5.25    |
| Withdrawal (30 days)           | 266.00 ± 9.85      | 285.40 ± 4.69           | 404.65 ± 10.08 | 142.98 ± 0.69 | 47.98 ± 0.69 | 106.44 ± 6.99 | 105.96 ± 2.89   |

a = p < 0.001, b = p < 0.01.
Table 5: Sperm motility, sperm density and fertility rate of control, [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] and [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated and withdrawal group of rats. Values are mean ± SE.

| Group                  | Sperm motility (%) | Sperm density (million/mL) | Fertility (%) |
|------------------------|--------------------|-----------------------------|---------------|
|                        |                    | Cauda epididymis            | Testis        |               |
| Control                | 60.79 ± 1.29       | 53.54 ± 0.38                | 5.29 ± 0.87   | 100% +ve      |
| [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] | 25.55 ± 1.59\textsuperscript{a} | 13.54 ± 2.50\textsuperscript{a} | 1.30 ± 0.12\textsuperscript{a} | 90% -ve |
| Withdrawal (30 days)   | 62.95 ± 4.57       | 20.55 ± 4.93                | 2.25 ± 0.35   | 25% +ve       |
| [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] | 36.90 ± 2.45\textsuperscript{a} | 19.99 ± 2.98\textsuperscript{a} | 1.28 ± 0.28\textsuperscript{a} | 72.0% -ve |
| Withdrawal (30 days)   | 67.98 ± 1.24       | 20.50 ± 3.54                | 1.35 ± 3.54   | 42.0% +ve     |

\textsuperscript{a} = p < 0.001, \textsuperscript{b} = p < 0.01.

Table 6: Protein, sialic acid, fructose and cholesterol concentration of control, and [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] and [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated and withdrawal group of rats. Values are mean ± SE.

| Group                  | Control                        | [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] | Withdrawal (30 days) | [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] | Withdrawal (30 days) |
|------------------------|-------------------------------|-------------------------------------------------|----------------------|-------------------------------------------------|----------------------|
| Protein (mg/g)         |                               |                                                 |                      |                                                 |                      |
| Testis                 | 85.04 ± 4.30                  | 75.09 ± 5.89                                   | 107.70 ± 8.88        | 32.57 ± 4.57                                    | 80.45 ± 1.40         |
| Cauda epididymis       | 56.40 ± 2.70                  | 50.24 ± 4.23                                   | 65.10 ± 7.23         | 42.88 ± 1.29                                    | 50.99 ± 4.20         |
| Ventral prostate       | 130.09 ± 3.10                 | 124.48 ± 9.64                                  | 120.99 ± 15.18       | 83.09 ± 2.50                                    | 144.09 ± 1.26        |
| Sialic acid (mg/g)     |                               |                                                 |                      |                                                 |                      |
| Testis                 | 1.18 ± 0.05                   | 0.65 ± 0.03                                    | 0.72 ± 0.03          | 0.83 ± 0.015                                    | 0.79 ± 0.03          |
| Cauda epididymis       | 0.95 ± 0.007                  | 0.56 ± 0.007                                   | 0.71 ± 0.02          | 0.82 ± 0.029                                    | 0.83 ± 0.006         |
| Cholesterol (mg/g)     |                               |                                                 |                      |                                                 |                      |
| Adrenal                | 14.50 ± 0.30                  | 22.49 ± 1.58                                   | 18.25 ± 0.07         | 27.19 ± 1.75                                    | 10.88 ± 0.40         |
| Testis                 | 6.13 ± 0.30                   | 15.99 ± 1.20                                   | 7.82 ± 0.09          | 7.64 ± 0.09                                     | 7.20 ± 0.10          |
| Fructose (mg/g)        |                               |                                                 |                      |                                                 |                      |
| Seminal vesicle        | 0.25 ± 0.014                  | 0.13 ± 0.004                                   | 0.22 ± 0.012         | 0.17 ± 0.003                                    | 0.28 ± 0.028         |

\textsuperscript{a} = p < 0.001, \textsuperscript{b} = p < 0.01.

in fertility rate was observed in the animals treated with [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] (Table 5).

**Biochemical changes**

**Proteins**

The protein concentration of the reproductive organs was lowered after the treatment of [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] as compared to the control which was brought to the normal level in testis and cauda epididymis after the withdrawal of the drug (Table 6). A significant reduction in the protein contents of testis (p < 0.001), cauda epididymis (p < 0.01), and ventral prostate (p < 0.001) was observed following the treatment of [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}]. The above changed parameters were restored completely to normal in all the organs after the withdrawal of the drug (Table 6).

**Sialic acid**

The testicular and cauda epididymal sialic acid concentration of [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] and [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated animals decreased significantly (p < 0.001). Withdrawal period of 30 days did not bring much change in the above content (Table 6).

**Fructose**

The fructose concentration of seminal vesicle was diminished significantly (p < 0.001) in [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] and [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated animals, which was recovered to the normal level after the withdrawal of the drug (Table 6).

**Cholesterol**

The cholesterol and testicular cholesterol content of adrenal increased significantly in [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] and [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated animals in comparison to the control. Withdrawal of the treatment attained the normal cholesterol and testicular cholesterol level (Table 6).

**Glycogen**

The glycogen concentration of testis was reduced in [Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] treated animals as compared to the control, whereas an increase was observed in the testicular glycogen level in [Fe(TAML\textsubscript{2})(CH\textsubscript{3}COO)\textsubscript{2}] treated group. The above altered parameter was restored completely after the withdrawal of the treatments (Table 7).

[Fe(TAML\textsubscript{1})(CH\textsubscript{3}COO)\textsubscript{2}] treated group also resulted in a significant reduction in the liver glycogen concentration.
Glycogen (mg/g) | Ventral prostate | Testis | Cauda epididymis | Acid phosphatase (mg/g/h) | Alkaline phosphatase (mg/g/h) |
|----------------|----------------|--------|-----------------|--------------------------|-----------------------------|
| Control        | 3.50 ± 0.27    | 22.92 ± 0.85 | 0.17 ± 0.002 | 5.45 ± 0.42 | 2.21 ± 0.19 |
| [Fe(TAML1)(CH3COO)2] | 3.35 ± 0.19 | 10.17 ± 0.77 | 0.13 ± 0.004 | 2.19b ± 0.017 | 1.39c ± 0.16 |
| Withdrawal (30 days) | 3.69 ± 0.29 | 20.88 ± 0.22 | 0.12b ± 0.002 | 6.23 ± 0.26 | 2.50 ± 0.29 |
| [Fe(TAML2)(CH3COO)2] | 4.38 ± 0.34 | 23.19 ± 0.32 | 0.11b ± 0.003 | 2.25 ± 0.23 | 1.57c ± 0.19 |
| Withdrawal (30 days) | 3.18 ± 0.46 | 11.97 ± 0.77 | 0.17 ± 0.006 | 3.87 ± 0.49 | 1.23 ± 0.25 |

\( a = p < 0.001, b = p < 0.01 \) and \( c = p < 0.05 \).

\( p < 0.001 \), which was brought to normal after the withdrawal of the treatment. On the contrary, an increase in the concentration of liver glycogen was evident following the withdrawal (Table 7).

Ascorbic acid

Treatment with both the groups resulted in reduction in the ascorbic acid concentration of testis. This decrease was more significant \( (p < 0.001) \) in \([Fe(TAML1)(CH3COO)2]\) treated group of rats. A decline in the ascorbic acid concentration was also noticed in cauda epididymis in both the treated groups. The decrease was more significant \( (p < 0.01) \) in \([Fe(TAML1)(CH3COO)2]\). The above altered parameter was brought to normal following 30 days withdrawal of the drug (Table 7).

Acid and alkaline phosphatase

A significant decrease in the acid phosphatase content \( (p < 0.01) \) of ventral prostate was observed in the \([Fe(TAML1)(CH3COO)2]\) and \([Fe(TAML2)(CH3COO)2]\) treated groups, which was completely restored to normal after the withdrawal in \([Fe(TAML1)(CH3COO)2]\). However, a partial recovery was observed in \([Fe(TAML1)(CH3COO)2]\) treated group of animals (Table 7). Similar reduction was also evidenced in the concentration of alkaline phosphatase content \( (p < 0.05) \) of ventral prostate of both the groups.

Haemoglobin and serum biochemistry

Haemoglobin and haematocrit values remained unaltered, indicating normal blood physiology of all the groups of animals. However, treatment with \([Fe(TAML1)(CH3COO)2]\) resulted in increased serum cholesterol concentration \( (p < 0.01) \). The concentrations of VLDL, triglycerides, albumin and A/G ratio were decreased. Treatment with \([Fe(TAML1)(CH3COO)2]\) also caused a significant increase in the serum cholesterol concentration \( (p < 0.01) \) while concentration of VLDL \( (p < 0.05) \), triglycerides \( (p < 0.05) \), albumin, and A/G ratio decreased. The protein and globulin concentration of serum was increased to some extent in both the treated groups of the animals.

The changes which have been found in the investigating parameters are found to be restoring to the normal partially or completely ultimately recovered. The results (Table 8) indicated that haemoglobin, haematocrit, protein, and albumin were restored completely following withdrawal of the test compounds. However, VLDL, serum, A/G ratio, and globulin were restored partially after 30 days of the stoppage of the compounds administration.

Serum testosterone

The ELISA test (Table 9) revealed a significant reduction \( (p < 0.05) \) in circulating serum testosterone in both the treated groups. Withdrawal of the drug for 30 days restored the level of serum testosterone completely in \([Fe(TAML1)(CH3COO)2]\) withdrawal group of rats while partial recovery was observed in \([Fe(TAML2)(CH3COO)2]\) withdrawal group of animals.

Histocytometry

The histocytometric data of \([Fe(TAML1)(CH3COO)2]\) treated rats revealed a decrease in the seminiferous tubule diameters, germinal epithelial cell height \( (p < 0.001) \), and Leydig cell diameter \( (p < 0.001) \) of testis along with a significant decrease in the epithelial cell height \( (p < 0.001) \) and muscle layer thickness \( (p < 0.001) \) of cauda epididymis. The epithelial cell height of seminal vesicle also decreased as compared to the control. A significant decrease was noticed in the epithelial cell height \( (p < 0.05) \) of ventral prostate and in the muscle layer thickness and epithelial cell height \( (p < 0.05) \) of vas deferens. The above altered parameters were restored following the withdrawal of the treatment (Table 10). In \([Fe(TAML1)(CH3COO)2]\) treated rats, a significant decrease was noticed in testicular seminiferous tubule diameter \( (p < 0.001) \), germinal epithelial cell height \( (p < 0.001) \), and Leydig cell diameter \( (p < 0.01) \). The epithelial cell height of cauda epididymis decreased significantly \( (p < 0.001) \) with a decrease in muscle layer thickness. A significant decrease in the epithelial cell height of seminal vesicle \( (p < 0.001) \) and ventral prostate \( (p < 0.001) \) was observed. The muscle layer thickness and epithelial cell height of vas deferens were also decreased. Withdrawal of the drug regained the normal levels (Table 11).
Table 8: Haematology and serum biochemistry of control, [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2] treated and withdrawal groups of rats. Values are mean ± SE, VLDL represents very low density lipoproteins, Tg denotes triglycerides, A/G ratio denotes albumin/globulin ratio.

| Group          | Control            | [Fe(TAML1)(CH3COO)2] | Withdrawal (30 days) | [Fe(TAML2)(CH3COO)2] | Withdrawal (30 days) |
|----------------|--------------------|----------------------|----------------------|----------------------|----------------------|
| Blood          |                    |                      |                      |                      |                      |
| Haemoglobin (%)| 13.97 ± 0.04       | 13.23 ± 0.16         | 13.74 ± 0.04         | 13.54 ± 0.14         | 13.37 ± 0.30         |
| Haematocrit (%)| 47.08 ± 0.39       | 44.89 ± 0.40         | 45.76 ± 0.39         | 46.29 ± 0.20         | 46.03 ± 0.40         |
| Serum          |                    |                      |                      |                      |                      |
| Protein (G/dL) | 6.97 ± 0.09        | 7.98 ± 0.13          | 9.99 ± 1.43          | 9.52 ± 0.39          | 8.09 ± 0.13          |
| Cholesterol (mg/dL) | 52.04 ± 0.87 | 64.23 ± 0.45         | 59.67 ± 0.56         | 64.99 ± 0.45         | 61.88 ± 0.54         |
| VLDL (mg/dL)   | 23.54 ± 1.09       | 22.23 ± 1.07         | 19.55 ± 0.88         | 26.98 ± 0.75         | 14.98 ± 0.76         |
| Tg (mg/dL)     | 114.24 ± 3.97      | 110.55 ± 1.34        | 93.45 ± 0.91         | 137.35 ± 0.78        | 76.55 ± 0.77         |
| Albumin (G/dL) | 3.29 ± 0.03        | 3.45 ± 0.02          | 3.81 ± 0.02          | 3.66 ± 0.01          | 3.10 ± 0.02          |
| A/G ratio      | 0.99 ± 0.04        | 0.68 ± 0.03          | 0.51 ± 0.02          | 0.59 ± 0.02          | 0.64 ± 0.02          |
| Globulin       | 3.47 ± 0.23        | 4.89 ± 0.02          | 6.50 ± 1.11          | 5.71 ± 0.19          | 4.88 ± 0.12          |

b = p < 0.01
c = p < 0.05.

Table 9: Effect of the test substances on serum testosterone content of control, [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2] treated, and withdrawal group of rats. Values are mean ± SE.

| Group          | Serum testosterone (mg/mL) |
|----------------|----------------------------|
| Control        | 1.3973 ± 0.076             |
| Fe(TAML1)(CH3COO)2 | 0.5975 ± 0.002²          |
| (50 mg/day/rat for 60 days) |                        |
| Withdrawal (30 days) | 0.83 ± 0.03             |
| Fe(TAML2)(CH3COO)2 | 0.675 ± 0.002²           |
| (50 mg/day/rat for 60 days) |                        |
| Withdrawal (30 days) | 1.81 ± 0.039            |

a = p < 0.001.

Discussion

In the present study, the results indicated that the weights of the body and vital organs were not affected after the treatment suggesting that the complexes have no side effect or toxicological effect and maintained normal physiology of the animals throughout the experiment.

(i) NJ Chinoy and MR Chinoy [24] reported that the structural and functional integrity of the reproductive organs depends on the circulating level of the androgen, and any small change in the androgen level results in the reduction in the weights of the reproductive organs. In the present studies, decline in the circulating levels of testosterone was observed in [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2] treated animals leading to a decrease in the organ weights and androgen-dependent parameters.

(ii) The reduction in the weight of the testis after the treatment in the present study related to the loss of spermatozoa and spermatids, which make up a substantial proportion of testicular volume, by the same token, as a consequence of disruption of spermatogenesis [25–27].

(iii) The suppressed epididymal activity as evidenced by the loss of the weight and histological alterations might be due to antagonadotropic activity of the so-termed antiandrogenic/estrogenic substances which lower the ABP production by the sertoli cell and androgen synthesis by the Leydig cells, thereby resulting in reduced levels of androgen available to the epididymis for functional maintenance. The requirement of relatively higher androgen threshold in the epididymis has already been established by Gupta et al [28].

(iv) Reduction in the weights of seminal vesicles, ventral prostate, and vas deferens, also reflects an interference with androgen output. Bhivgade et al [29] have already correlated the reduction in the weights of sex accessories, particularly of the prostate, following treatment of cyproterone acetate. Antiandrogens are known to depress the uptake of testosterone in the prostate and reduce binding of androgen to the hormonal receptors by a process of competitive inhibition as reported by Sharma and Jacob [30].

(v) The sperm density and sperm motility have a direct relationship to the fertility [31]. In the present study, sperm motility and density of testis and cauda epididymis after [Fe(TAML1)(CH3COO)2] and [Fe(TAML2)(CH3COO)2] treatments were significantly declined. Rao [32] has reported declined sperm motility, resulting into decreased fertility.

Immotile or sluggishly motile spermatozoa cannot penetrate the cervical mucus, thus fail to fertilize the ova [33]. During the present course of the study, 90% negative fertility rate was observed after [Fe(TAML1)(CH3COO)2] treatment, while it was 72% negative in the [Fe(TAML2)(CH3COO)2] treated animals. It appears worthwhile to conclude that reduction in the sperm counts and motility recorded in treated animals substantiates the antifertility activity. Further, alteration in the various androgen-dependent biochemical parameters that in turn altered the internal milieu of the epididymis [34] may also be responsible for the negative fertility test. Withdrawal for 30 days in the groups treated with
and 

\[ \text{[Fe(TAML1)(CH}_3\text{COO})_2] \]

and

\[ \text{[Fe(TAML2)(CH}_3\text{COO})_2] \] 

showed significant recovery in the fertility rate, indicating that the effects brought about the synthetic compounds were reversible.

(vi) Protein is involved in the alteration of almost every physiological system and the total protein run parallel to the growth and is sensitive to estrogen and androgen, respectively, reported by Davis et al. [35], Jones [36] has reported that protein level is directly correlated with the secretory activity of the epididymis, which in turn depends on the androgen levels.

In the present investigations, the reduction in the protein concentration by the treatment may be attributed to the reduction in secretory activity because of the androgen deprivation effect. Kamal et al. [4] and Mali et al. [37] also reported similar results for the male albino rats.

(vii) Nag et al. [38] have reported that an optimal level of sialic acid in reproductive organs is essential for functional integrity of spermatozoa. Our observations are in consonance with those of Gupta and Ahmed [39] who have reported a decrease in sialic acid concentration of testis, cauda epididymis, seminal vesicle, and ventral prostate to albino rats. Bhargava [40] reported decrease in the testicular sialic acid concentration due to the antispermatogenic activity.

(viii) Mammalian cells require cholesterol which plays an important role in acting as precursor molecule in the synthesis of steroid hormone [41]. The requirement of cholesterol for normal activity of testicular glands has been well established by Biswas, Deb, and Johnson [42, 43]. Androgens are synthesized from cholesterol, but increased concentration may result in the reduction of fertility [44].

After the treatment with the effective doses of both the compounds, there was a significant increase in the testicular and adrenal cholesterol concentration which is in consonance with the results of Kamal et al. [4], suggesting that the increased testicular cholesterol concentration may be correlated with its nonutilization by the system leading to a fall in circulatory androgen in rats due to the antiandrogenic activity.

(ix) Baijal et al. [45] proposed that glycogen might represent a source of nourishment for the spermatozoa during its development and maturation. The glycogen level declined in testis and liver of the rats treated with \[ \text{[Fe(TAML1)-(CH}_3\text{COO})_2] \]. Kamal et al. [4] have reported decreased concentration of glycogen in the rats due to its androgen dependence, leading to various disorders in testis.

In contrast, treatment with \[ \text{[Fe(TAML2)(CH}_3\text{COO})_2] \] caused a nonsignificant increase in the concentration of glycogen of both the liver and testis. The same case has been
reported by Ewing et al [46]. Increased carbohydrate utilization has been considered due to androgenic stimulation suggesting a direct correlation between testosterone secretion rate and glucose uptake by the isolated and perfused rabbit testis as reported by Ewing et al [46].

(x) After treatment with effective doses of [Fe(TAML1)-(CH3COO)2] and [Fe(TAML2)(CH3COO)2], there was a decrease in the testicular and cauda epididymal ascorbic acid concentration, which is in consonance with that of Chaterjee et al [47] who reported hypofunctioning of testis and the degeneration of the germinal epithelium due to vitamin C deficiency.

(xi) Decline in acid phosphate level might be due to antiandrogenic effect or might be due to suppressed secretory function of the prostate [28, 32, 44]. The acid phosphate values during present course of the study concur with the findings of Jacob et al [48].

Administration of the test substances resulted in a significant reduction in the alkaline phosphate content of the ventral prostate. It is evident that this decrease was a likely consequence of spermatogenic arrest as a result of suppression of androgenesis. This observation concurs with the findings of others also [4, 44, 48], who reported a general decline in the alkaline phosphate content of the various reproductive and accessory organs of the male rats after androgen-estrogen therapy.

ACKNOWLEDGMENT

One of the authors (Ashu Chaudhary) is indebted to Council of Scientific and Industrial Research, New Delhi, for financial assistance in the form of Research Associateship, vide Grant no. 9/149/(374)/2004/EMR-1 and also is thankful to Dr. Preeti Saxena for her help in interpreting the antifertility data.

REFERENCES

[1] Bhakuni DS, Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN. Screening of Indian plants for biological activity. II. Indian Journal of Experimental Biology. 1969;7(4):250–262.
[2] Dixit SK, Bhatt GK. Folk-lore studies on unknown indigenous antifertility drugs. The Journal of Research in Indian Medicine. 1975;10(3):77–81.
[3] Dhawan BN, Patnaik GK, Rastogi RP, Singh KK, Tandon JS. Screening of Indian plants for biological activity; part VI. Indian Journal of Experimental Biology. 1977;15(3):208–219.
[4] Kamal R, Yadav R, Sharma JD. Efficacy of the steroidal fraction of fenugreek seed extract on fertility of male albino rats. Phytotherapy Research. 1993;7(2):134–138.
[5] Sharma S, Sharma RK, Sharma R, Sharma A, Rai AK, Gupta RS, Singh Y. Synthesis and characterisation of some new aluminium derivatives of Schiff bases containing N, O and S donor atoms and the anti fertility activity of the derivative Al[SC6H4N:C(CH3)CH2COCH3], Bioinorganic Chemistry and Applications. 2003;1(3-4):215–225.
[6] Saxena C, Singh RV, Joshi SC. Spectroscopic characterization and in vitro and in vivo screening of difluoro-boron complexes. Bulletin of the Chemical Society of Japan. 1994;67:1007–1010.
[7] Sharma K, Joshi SC, Singh RV. Fertility inhibitor heterobimetallic complexes of platinum(II) and palladium(II): synthetic, spectroscopic and antimicrobial aspects. Metal-Based Drugs. 2000;7(2):105–113.
[8] Jain M, Gaur S, Diwedi SC, Joshi SC, Singh RV, Bansal A. Nematicidal, insecticidal, antifertility, antifungal and antibacterial activities of salicylanilide sulphaphthazole and its manganese, silicon and tin complexes. Phosphorus, Sulfur, and Silicon and the Related Elements. 2004;179(8):1517–1537.
[9] Singh RV, Dwivedi R, Joshi SC. Synthetic, magnetic, spectral, antimicrobial and antifertility studies of dioxygenohydroxynickel(VI) unsymmetrical imine complexes having a N N donor system. Transition Metal Chemistry. 2004;29(1):70–74.
[10] Fahmi N, Bansal A, Joshi SC, Singh RV. Effects of manganese(II) complexes of [2-1-thienyl]ethylidene] hydrazine-carbo-thioamide on reproductive function of male rats. Asian Journal of Chemistry. 1999;9:1488–1496.
[11] Karlin KD, Zubieta J, eds. Copper Coordination Chemistry: Biochemical and Inorganic Perspectives. Vol 113. New York, NY: Adenine Press; 1983.
[12] Prasad MRR, Chinoy NJ, Kadam KM. Changes in succinic dehydrogenase levels in the rat epididymis under normal and altered physiologic conditions. Fertility and Sterility. 1972;23(3):186–190.
[13] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry. 1951;193(1):265–275.
[14] Warren L. The thiobarbituric acid assay of sialic acids. The Journal of Biological Chemistry. 1939;234(8):1971–1975.
[15] Zlatkis A, Zak B, Boyle AJ. A new method for the direct determination of serum cholesterol. The Journal of Laboratory and Clinical Medicine. 1953;41(3):486–492.
[16] Montgomery R. Determination glycogen. Archives of Biochemistry and Biophysics. 1957;67(2):378–386.
[17] Foreman D, Gaylor L, Evans E, Trella C. A modification of the Roe procedure for determination of fructose in tissues with increased specificity. Analytical Biochemistry. 1973;56(2):584–590.
[18] Roe JH, Kuether CA. The determination of ascorbic acid in whole blood and urine through the 2,4-dinitrophenylhydrazine derivative of dehydroascorbic acid. The Journal of Biological Chemistry. 1943;147(2):399–407.
[19] Fiske CMH, Subbarow Y. Practical Physiological Chemistry. 4th ed. New York, NY: McGraw-Hill; 1965.
[20] Nanda KK, Dutta SK, Adhikary B. Synthesis and characterization of tetraneuclear nickel(II) complex with a macroyclic ligand. Indian Journal of Chemistry. 1995;34A:64–73.
[21] Malon M, Travniczek Z, Marysko M, et al. Metal complexes as anticancer agents 2. Iron(III) and copper(II) bio-active complexes with N6-benzylaminopurine derivatives. Inorganic Chemistry Acta. 2001;323(1-2):119–129.
[22] Lobana TS, Cheema HS, Sandhu SS. Chemistry of iron complexes—IV. Spectroscopic, magnetic and other properties of complexes of iron(II) iodide and iron(II) tetracarbonyl iodide with b. Polyhedron. 1985;4(4):717–721.
[23] Chaudhary A, Jaroli DP, Singh RV. Antimicrobial, antifertility and antiinflammatory approach to tetradeutate macrocyclic complexes of iron(II) and manganese (II). Metal-Based Drugs. 2001;8(6):347–353.
[24] Chinoy NJ, Chinoy MR. Effects of chronic administration of aluminium chloride on reproduction of the testes and some accessory sex organs of male rats. J. Reproductive Biology Comp. Endocrinology. 1982;2(1):1–9.
[25] Gupta RS, Bhatnager AK, Joshi YC, Sharma R, Sharma A. Suppression of fertility in male albino rats following α-amyrin acetate administration. *Pharmaceutical Biology.* 2004;42(2):98–104.

[26] Dobhal MP, Shabbir AS, Pranvir P, Gupta RS. Biologically active constituents isolated from medicinal plants. *Himalayan Chemical and Pharmaceutical Bulletin.* 2000;17:22–26.

[27] Mathur P, Vyas DK, Sharma N, Jacod D. Abstract. In: International Symposium on Male Contraception: Present and Future; November 1995; New Delhi, India. 27.

[28] Gupta G, Rajalakshmi M, Prasad MRN, Moudgal NR. Alteration of epididymal function and its relation to maturation of spermatozoa. *Andrologia.* 1974;6(1):35–44.

[29] Bhargave DA, Menon SN, Avari KM. Effect of cyproterone acetate on testis of albino rats: ultrastructural and biochemical approach. *Indian Journal of Experimental Biology.* 1990;28(3):201–207.

[30] Sharma N, Jacob D. Fertility suppression of the male mouse after administration of mint leaf extract. *Phytotherapy Research.* 1996;10(2):175–177.

[31] David G, Jouannet P, Martin-Boyce A, Spira A, Schwartz D. Sperm counts in fertile and infertile men. *Fertility and Sterility.* 1979;31(4):453–455.

[32] Rao MV, Thakor F, Shiney G, Shah KD, Roy GK. Contraceptive efficacy of testosterone enanthate in males. *Journal of Animal Morphology and Physiology.* 1996;43(1):15–21.

[33] Amelar RD, Dubin L, Schoenfeld C. Sperm motility. *Fertility and Sterility.* 1980;34(3):197–215.

[34] Gupta RS, Sharma R, Sharma A, et al. Antispermatogenic effect and chemical investigation of Opuntia dillenii. *Pharmaceutical Biology.* 2002;40(6):411–415.

[35] Watson HL, Davidson MK, Cox NR, Davis JK, Dybvig K, Cassell GH. Protein variability among strains of mycoplasma pulmonis. *Infection and Immunity.* 1987;55(11):2838–2840.

[36] Jones R. Effects of testosterone, testosterone metabolites and anti-androgens on the function of the male accessory glands in the rabbit and rat. *Journal of Endocrinology.* 1977;74(1):75–88.

[37] Mali PC, Chatuvedi M, Dixit VP. Antispermatogenic activity of Solanum xanthocarpum S and W root (50 percent EtOH extract) in rats. *Journal of Phytological Research.* 1996;9(1):13–17.

[38] Nag S, Sarkar D, Ghosh JJ. Sialic acid & sialidase activity in rat testis & epididymis in relation to age & action of different antifertility agents. *Indian Journal of Experimental Biology.* 1977;15(7):510–512.

[39] Gupta DR, Ahmed B. Emarginatosides B and C: Two new saponins from Sapindus emarginatus fruits. *Indian Journal of Chemistry.* 1991;29B:268–270.

[40] Bhargava SK. Anti-spermatogenic activity of malvidin chloride in langur monkeys (Presbytis entellus entellus Dufresne). *International Journal of Andrology.* 1990;13(3):207–215.

[41] Gupta SK. Current status of development and clinical testing of male intravasal contraceptives (Abstr.). In: International Symposium on Male Contraception: Present and Future; November 1995; New Delhi, India. 6.

[42] Biswas NM, Deb C. Testicular degeneration in rats during hypervitaminosis A. *Endocrinologie.* 1965;49(1):64–69.

[43] Johnson AD. Testicular lipids. In: Johnson AD, Gomes WR, Van Demark NL, eds. *The Testis.* Vol 2. New York, NY: Academic Press; 1967.

[44] Garg SK, Mathur VS, Chaudhury RR. Screening of Indian plants for antifertility activity. *Indian Journal of Experimental Biology.* 1978;16(10):1077–1079.

[45] Chinoy NJ, Mehta D. Beneficial effects of the amino acids glycine and glutamine on testis of mice treated with sodium fluoride. *Fluoride.* 1999;32(3):162–170.

[46] Ewing LL, Means AR, Beames CG Jr, Montgomery RD. Biochemical changes in rat testis during postnatal maturation. *Journal of Reproduction and Fertility.* 1966;12(2):295–307.

[47] Chaterjee A, Adhikari P, Benerji J, Choudhury C, Jana S, Sen Gupta A. Antifertility effect of Piper beetle Linn. (Stalk) in adult male rats. *Journal of the Indian Chemical Society.* 1994;71:81–84.

[48] Sharma MM, Lal G, Jacob D. Effects of low doses of chloromadinone acetate in the rat. *Journal of Reproduction and Fertility.* 1976;48(1):177–179.